Global Polyclonal Antibodies Market Size Study & Forecast, by Product Type (Primary Antibody, Secondary Antibody), By Application (Academic Research, Commercial) and Regional Analysis, 2023-2030

Global Polyclonal Antibodies Market Size Study & Forecast, by Product Type (Primary Antibody, Secondary Antibody), By Application (Academic Research, Commercial) and Regional Analysis, 2023-2030

Global Polyclonal Antibodies Market is valued at approximately USD 1054.24 million in 2022 and is anticipated to grow with a growth rate of more than 5.70% over the forecast period 2023-2030. Polyclonal antibodies are a type of antibodies that are derived from the immune response of an animal, typically a mammal, in response to the introduction of an antigen. Polyclonal antibodies are a heterogeneous mixture of antibodies produced by different B-cells, each recognizing a different epitope on the antigen. The production of polyclonal antibodies in animals necessitates the administration of the same antigen repeatedly. They are an amalgam of antibodies made by many B-cell lineages. These antibodies are a group of immunoglobulin molecules that bind to certain antigens and recognize various antigen epitopes. Inoculating a suitable mammal, like a rabbit, mouse, or goat, with a virus produces antibodies frequently. After the mammal receives the antigen, B cells produce immunoglobulin G (IgG) that is exclusive to that antigen. The market growth is anticipated to rise as a result of the progressive healthcare industry, growing neurobiology and stem cell research, and the accessibility of high-tech products.

Additionally, an increase in the incidences of infectious and chronic diseases and a rise in cancer prevalence are predicted to boost the global polyclonal antibody market. The World Cancer Research Fund International estimates that globally approximately 18.1 million new cases of cancer were recorded in 2020, in which 9.3 million of these instances involved men, while 8.8 million involved women. Furthermore, Major pharmaceutical and biotechnology businesses are also expected to expand their research and development efforts globally, creating various growth prospects for the market. Additionally, Industry leaders in the global polyclonal antibody market employ a range of strategies, including alliances, mergers and acquisitions, and collaboration, which is likely to present the industry with multiple growth opportunities . However, the market for polyclonal antibodies is expected to face challenges from factors such as the high price of research antibodies and the low purity and concentration levels of some of these antibodies throughout the forecast period of 2023-2030.

The key regions considered for the Global Polyclonal Antibodies Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the region's high concentration of top players and ongoing research & development activities. Asia-Pacific is expected to grow with the fastest CAGR over the projected period of 2023-2030. Factors such as the rising rates of cancer and other disorders, advancements in healthcare infrastructure in countries such as India, China, and South Korea, increasing demand for personalized medicine as well as the rising demand for therapeutic antibodies in the region.

Major market players included in this report are:
Thermo Fisher Scientific Inc.
Merck KGaA
Abcam plc
Bio-Rad Laboratories Inc.
Cell Signaling Technology Inc.
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Agilent Technologies
PerkinElmer Inc.
BioLegend, Inc

Recent Developments in the Market:
In October 2022, The Binding Site consortium is acquired by Thermo Fisher Scientific Inc. with USD 2.6 billion as of the time of publishing from a consortium of stockholders led by the European private equity firm Nordic Capital.

Global Polyclonal Antibodies Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Primary Antibody
Secondary Antibody

By Application:
Academic Research
Commercial
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Thermo Fisher Scientific Inc.
Merck KGaA
Abcam plc
Bio-Rad Laboratories Inc.
Cell Signaling Technology Inc.
F. Hoffmann-La Roche Ltd.
Danaher Corporation
Agilent Technologies
PerkinElmer Inc.
BioLegend, Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.